WHO Expert Groups Assess Candidate Treatments and Vaccines for Bundibugyo Virus Disease Outbreak in DRC and Uganda (who.int)

• WHO R&D Blueprint and SAGE advised on candidate vaccines and therapeutics for BVD.
• Priority therapeutics: MBP134, Maftivimab, remdesivir; combination therapy recommended.
• Post-exposure prophylaxis: oral obeldesivir for contacts.
• Vaccine candidates: rVSV Bundibugyo (IAVI) and ChAdOx1 Bundibugyo (Oxford/Serum Institute).
• Ervebo not recommended for BVD outside research.
• Clinical trials to be conducted with DRC, Uganda, Africa CDC, ANRS.

"In response to the ongoing Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo and Uganda, WHO convened expert groups to evaluate candidate medical countermeasures. There are no licensed therapies for BVD. For treatment, experts prioritized monoclonal antibodies MBP134 and Maftivimab, and antiviral remdesivir, including combinations. For post-exposure prophylaxis, oral obeldesivir was recommended. Two candidate vaccines were identified: rVSV Bundibugyo (IAVI, 7-9 months) and ChAdOx1 Bundibugyo (Oxford/Serum Institute, 2-3 months, pending animal data). Ervebo, licensed for other Ebola species, is not recommended outside research. WHO is working with DRC, Uganda, Africa CDC, and partners to implement clinical trials."